# Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)

> **NCT01279590** · PHASE2 · COMPLETED · sponsor: **Furiex Pharmaceuticals, Inc** · enrollment: 282 (actual)

## Conditions studied

- Myalgia
- Hypercholesterolemia
- Hyperlipidemia

## Interventions

- **DRUG:** PPD10558
- **DRUG:** Atorvastatin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01279590
- **Lead sponsor:** Furiex Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 282 (ACTUAL)
- **Last updated:** 2011-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01279590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01279590, "Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01279590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*